Ranbaxy records consistent improvement in operating performance

Ranbaxy Laboratories, an Indian major, has posted net sale of $356m for Q3, 2009, a de-growth of 18% over Q3, 2008. EBITDA was $45m, a margin of 13% to sales. The company also recorded profit before tax as $33m and profit after tax as $24m.

For the nine month ended period, the company recorded a net sales of $1,037m with EBITDA of $32m. It also recorded profit before tax as $15m and profit after tax as $10m.

Atul Sobti, managing director and CEO at Ranbaxy, said: “We are pleased with the consistent quarter-on-quarter improvement in financial performance this year, in spite of continuing challenges in some key markets. Revenue growth in some strategic geographical markets, and a sharp focus on cost efficiency have been the underlying themes this quarter. With good achievements on these fronts, we are confident that we are on the path to recovery. We are also seeing greater traction in realizing synergies with Daiichi Sankyo, in building a stronger future for Ranbaxy.”